Pharmacological targeting of casein kinase 1δ suppresses oncogenic NRAS-driven melanoma

Abstract Activating mutations in NRAS account for 15–20% of melanoma, yet effective anti-NRAS therapies are still lacking. In this study, we unveil the casein kinase 1δ (CK1δ) as an uncharacterized regulator of oncogenic NRAS mutations, specifically Q61R and Q61K, which are the most prevalent NRAS m...

全面介紹

書目詳細資料

發表在:	Nature Communications
Main Authors:	Yalei Wen, Hui Wang, Xiao Yang, Yingjie Zhu, Mei Li, Xiuqing Ma, Lei Huang, Rui Wan, Caishi Zhang, Shengrong Li, Hongling Jia, Qin Guo, Xiaoyun Lu, Zhengqiu Li, Xiangchun Shen, Qiushi Zhang, Lu Si, Chengqian Yin, Tongzheng Liu
格式:	Article
語言:	英语
出版:	Nature Portfolio 2024-11-01
在線閱讀:	https://doi.org/10.1038/s41467-024-54140-1